{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:01:46Z","timestamp":1767859306361,"version":"3.49.0"},"reference-count":32,"publisher":"American Society for Microbiology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Vaccine Immunol."],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>AdVAV is a replication-deficient adenovirus type 5-vectored vaccine expressing the 83-kDa protective antigen (PA83) from<jats:named-content content-type=\"genus-species\">Bacillus anthracis<\/jats:named-content>that is being developed for the prevention of disease caused by inhalation of aerosolized<jats:named-content content-type=\"genus-species\">B. anthracis<\/jats:named-content>spores. A noninferiority study comparing the efficacy of AdVAV to the currently licensed Anthrax Vaccine Absorbed (AVA; BioThrax) was performed in New Zealand White rabbits using postchallenge survival as the study endpoint (20% noninferiority margin for survival). Three groups of 32 rabbits were vaccinated with a single intranasal dose of AdVAV (7.5 \u00d7 10<jats:sup>7<\/jats:sup>, 1.5 \u00d7 10<jats:sup>9<\/jats:sup>, or 3.5 \u00d7 10<jats:sup>10<\/jats:sup>viral particles). Three additional groups of 32 animals received two doses of either intranasal AdVAV (3.5 \u00d7 10<jats:sup>10<\/jats:sup>viral particles) or intramuscular AVA (diluted 1:16 or 1:64) 28 days apart. The placebo group of 16 rabbits received a single intranasal dose of AdVAV formulation buffer. All animals were challenged via the inhalation route with a targeted dose of 200 times the 50% lethal dose (LD<jats:sub>50<\/jats:sub>) of aerosolized<jats:named-content content-type=\"genus-species\">B. anthracis<\/jats:named-content>Ames spores 70 days after the initial vaccination and were followed for 3 weeks. PA83 immunogenicity was evaluated by validated toxin neutralizing antibody and serum anti-PA83 IgG enzyme-linked immunosorbent assays (ELISAs). All animals in the placebo cohort died from the challenge. Three of the four AdVAV dose cohorts tested, including two single-dose cohorts, achieved statistical noninferiority relative to the AVA comparator group, with survival rates between 97% and 100%. Vaccination with AdVAV also produced antibody titers with earlier onset and greater persistence than vaccination with AVA.<\/jats:p>","DOI":"10.1128\/cvi.00690-14","type":"journal-article","created":{"date-parts":[[2015,2,12]],"date-time":"2015-02-12T06:52:45Z","timestamp":1423723965000},"page":"430-439","source":"Crossref","is-referenced-by-count":25,"title":["Efficacy and Immunogenicity of Single-Dose AdVAV Intranasal Anthrax Vaccine Compared to Anthrax Vaccine Absorbed in an Aerosolized Spore Rabbit Challenge Model"],"prefix":"10.1128","volume":"22","author":[{"given":"Vyjayanthi","family":"Krishnan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo H.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Shoemaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria S.","family":"Sivko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin P.","family":"Tordoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory V.","family":"Stark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsungwei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Duchars","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Scot","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","published-online":{"date-parts":[[2015,2,11]]},"reference":[{"key":"key20180919073800_B1","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/35099687","article-title":"Genetic sleuths rush to identify anthrax strains in mail attacks","volume":"413","year":"2001","journal-title":"Nature"},{"key":"key20180919073800_B2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1749-6632.1980.tb18910.x","article-title":"Inhalation anthrax","volume":"353","year":"1980","journal-title":"Ann N Y Acad Sci"},{"key":"key20180919073800_B3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1001\/archinte.158.5.429","article-title":"Anthrax as a potential biological warfare agent","volume":"158","year":"1998","journal-title":"Arch Intern Med"},{"key":"key20180919073800_B4","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/S0041-0101(01)00161-1","article-title":"Toxins of Bacillus anthracis","volume":"39","year":"2001","journal-title":"Toxicon"},{"key":"key20180919073800_B5","doi-asserted-by":"publisher","first-page":"4768","DOI":"10.1016\/S0264-410X(01)00234-1","article-title":"In vitro correlate of immunity in a rabbit model of inhalational anthrax","volume":"19","year":"2001","journal-title":"Vaccine"},{"key":"key20180919073800_B6","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1128\/IAI.69.5.2888-2893.2001","article-title":"Search for correlates of protective immunity conferred by anthrax vaccine","volume":"69","year":"2001","journal-title":"Infect Immun"},{"key":"key20180919073800_B7","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1016\/j.vaccine.2005.12.028","article-title":"Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine","volume":"24","year":"2006","journal-title":"Vaccine"},{"key":"key20180919073800_B8","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.vaccine.2003.07.004","article-title":"Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine","volume":"22","year":"2004","journal-title":"Vaccine"},{"key":"key20180919073800_B9","doi-asserted-by":"publisher","first-page":"6947","DOI":"10.1073\/pnas.92.15.6947","article-title":"Prolonged survival of pancreatic islet allografts mediated by adenovirus immunoregulatory transgenes","volume":"92","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key20180919073800_B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/CVI.00280-12","article-title":"An adenovirus-vectored nasal vaccine confers rapid and sustained protection against anthrax in a single-dose regimen","volume":"20","year":"2013","journal-title":"Clin Vaccine Immunol"},{"key":"key20180919073800_B11","doi-asserted-by":"publisher","first-page":"10078","DOI":"10.1128\/JVI.77.18.10078-10087.2003","article-title":"Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system","volume":"77","year":"2003","journal-title":"J Virol"},{"key":"key20180919073800_B12","doi-asserted-by":"publisher","first-page":"11474","DOI":"10.1128\/JVI.75.23.11474-11482.2001","article-title":"Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines","volume":"75","year":"2001","journal-title":"J Virol"},{"key":"key20180919073800_B13","doi-asserted-by":"publisher","first-page":"e31177","DOI":"10.1371\/journal.pone.0031177","article-title":"Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin","volume":"7","year":"2012","journal-title":"PLoS One"},{"key":"key20180919073800_B14","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1128\/CVI.00560-13","article-title":"Intramuscular delivery of adenovirus serotype 5 vector expressing humanized protective antigen induces rapid protection against anthrax that may bypass intranasally originated preexisting adenovirus immunity","volume":"21","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"key20180919073800_B15","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1089\/104303403322542310","article-title":"Protective immunity evoked against anthrax lethal toxin after a single intramuscular administration of an adenovirus-based vaccine encoding humanized protective antigen","volume":"14","year":"2003","journal-title":"Hum Gene Ther"},{"key":"key20180919073800_B16","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/gt.2008.181","article-title":"An adenoviral vector-based mucosal vaccine is effective in protection against botulism","volume":"16","year":"2009","journal-title":"Gene Ther"},{"key":"key20180919073800_B17","doi-asserted-by":"publisher","first-page":"7613","DOI":"10.1016\/j.vaccine.2010.09.055","article-title":"Mucosal adenovirus-vectored vaccine for measles","volume":"28","year":"2010","journal-title":"Vaccine"},{"key":"key20180919073800_B18","volume-title":"Biothrax package insert","author":"Emergent BioSolutions","year":"2013"},{"key":"key20180919073800_B19","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.vaccine.2013.10.039","article-title":"Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: a randomized trial","volume":"32","year":"2014","journal-title":"Vaccine"},{"key":"key20180919073800_B20","volume-title":"Pathway to licensure for protective antigen-based anthrax vaccines for a postexposure prophylaxis indication using the animal rule","author":"US Food and Drug Administration"},{"key":"key20180919073800_B21","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1128\/CVI.00099-13","article-title":"Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis","volume":"20","year":"2013","journal-title":"Clin Vaccine Immunol"},{"key":"key20180919073800_B22","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1089\/hum.1998.9.13-1909","article-title":"New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses","volume":"9","year":"1998","journal-title":"Hum Gene Ther"},{"key":"key20180919073800_B23","first-page":"982","article-title":"The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation","volume":"122","year":"1998","journal-title":"Arch Pathol Lab Med"},{"key":"key20180919073800_B24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jim.2008.01.007","article-title":"Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization","volume":"333","year":"2008","journal-title":"J Immunol Methods"},{"key":"key20180919073800_B25","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1056\/NEJM199509283331302","article-title":"A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis","volume":"333","year":"1995","journal-title":"N Engl J Med"},{"key":"key20180919073800_B26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0361-9230(98)00042-2","article-title":"Suppression of inflammation by dexamethasone prolongs adenoviral vector-mediated transgene expression in the facial nucleus of the rat","volume":"47","year":"1998","journal-title":"Brain Res Bull"},{"key":"key20180919073800_B27","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.surg.2005.01.004","article-title":"Macrophage ablation attenuates adenoviral vector-induced pancreatitis","volume":"137","year":"2005","journal-title":"Surgery"},{"key":"key20180919073800_B28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/15376510802312464","article-title":"Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer's construct, or gene inserts","volume":"5","year":"2008","journal-title":"J Immunotoxicol"},{"key":"key20180919073800_B29","doi-asserted-by":"publisher","first-page":"e3548","DOI":"10.1371\/journal.pone.0003548","article-title":"Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice","volume":"3","year":"2008","journal-title":"PLoS One"},{"key":"key20180919073800_B30","doi-asserted-by":"publisher","first-page":"10129","DOI":"10.1073\/pnas.1631983100","article-title":"Modeling the optimum duration of antibiotic prophylaxis in an anthrax outbreak","volume":"100","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key20180919073800_B31","article-title":"Bichat guidelines for the clinical management of anthrax and bioterrorism-related anthrax","volume":"9","year":"2004","journal-title":"Euro Surveill"},{"key":"key20180919073800_B32","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1093\/infdis\/167.5.1239","article-title":"Postexposure prophylaxis against experimental inhalation anthrax","volume":"167","year":"1993","journal-title":"J Infect Dis"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1128\/CVI.00690-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:51:31Z","timestamp":1627591891000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00690-14"}},"subtitle":[],"editor":[{"given":"M. F.","family":"Pasetti","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,2,11]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,3,26]]},"published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1128\/CVI.00690-14"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00690-14","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,11]]}}}